1.
Bioorg Med Chem Lett
; 16(10): 2729-33, 2006 May 15.
Artigo
em Inglês
| MEDLINE
| ID: mdl-16504501
RESUMO
3-[6-(2-Dimethylamino-1-imidazol-1-yl-butyl)-naphthalen-2-yloxy]-2,2-dimethyl-propionic acid and analogs were designed and synthesized as highly potent and selective CYP26 inhibitors, serving as retinoic acid metabolic blocking agents (RAMBAs), with demonstrated in vivo efficacy to increase the half-life of exogenous atRA.